Targeted Oncology Therapeutics: Success of CAR-T Technology for the Treatment of Haematology Cancers

Dublin, Nov. 03, 2021 (GLOBE NEWSWIRE) -- The "Targeted Oncology Therapeutics: Hematology Cancers" report has been added to ResearchAndMarkets.com's offering.

There is a strong trend in oncology toward therapeutics that focus on specific targeting mechanisms to achieve positive outcomes.

The success of CAR-T technology for the treatment of haematology cancers has been a glowing example of the power of molecular manipulation to treat specific conditions.

More than three dozen targeted treatments, using novel pathways and signalling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. These approaches have attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological, and emotional burden of cancer. Efforts to re-focus and apply this technology to solid tumours is now aggressively being pursued by a growing list of market participants. This report examines leading mAb and kinase inhibitor therapeutic drugs and the biomarkers they utilize.

Target Oncology Haematology Cancers - What You Will Learn

• What is the market share of approved haematology cancer therapeutics?

• What is the global supply picture for targeted haematology cancer therapeutics?

• Who are the market leaders, by Indication? by Product?

• What is the therapeutic coverage across all oncology indications? What are the product opportunities?

• What are the established products in this space? by target, indication, API class, revenue?

• What is the competitive picture for the haematology cancer market segments?

• Drug treatment resources

• Competitive therapy map

• Clinical trial activity

• Who are the leading competitors in the field of next-generation haematology cancer therapeutics?

Key Topics Covered:

• Executive Summary

• Targeted Oncology Therapeutics

• Hematology Cancers

• Executive Summary

• The Recombinant Drug Ecosystem

• mAbs and Targeted Oncology Therapeutics

• Leukemias

• Acute Lymphocytic Leukemia

• Chronic Lymphocytic Leukemia

• Childhood Acute Lymphoblastic Leukemia

• Acute Myeloid Leukemia

• Chronic Myelogenous Leukemia

• Lymphomas

• Hodgkin Lymphoma

• Non-Hodgkin's Lymphoma

• Multiple Myeloma

• Biological Drugs for Hematology Cancers

• Monoclonal Antibodies (Twelve Therapeutic Products)

• Tyrosine Kinase Inhibitors

• ALL with Philadelphia chromosome (Ph+ ALL)

• FDA Approved TKIs (Six Therapeutic Products)

• Chimeric Antigen Receptor-T (CAR-T) (Five Products)

• The Therapeutic Market Landscape

• Diagnostic Tools

• Drugs in Development - The Clinical Trial Picture

• Leukemias

• Lymphomas

• Myeloma

• FDA-Approved Targeted Oncology

• Therapeutics for Hematology Cancers

Companies Mentioned

• Amgen

• Astellas

• AstraZeneca

• Bristol-Myers Squibb

• Celltrion

• Daiichi Sankyo

• Eli Lilly

• Genentech

• Genzyme

• GlaxoSmithKline

• Janssen Biotech

• Kyowa Kirin

• Merck Sharp & Dohme

• Mylan GmbH

• Pfizer

• Regeneron Pharmaceuticals

• Samsung Bioepis

• Spetrum Pharmaceuticals

• United Therapeutics

• Roche

• EMD Serono

• Immunex

• Lonza Biologics

• Lonza AG

• Seattle Genetics

• Biogen

For more information about this report visit https://www.researchandmarkets.com/r/6uxb44

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900